Hey there, welcome to Chasing Life.

You know, when Ozempik first hit the market in 2017, it was the start of a revolution.

The medication approved to treat type 2 diabetes was also helping people lose weight, sometimes a lot of it,

and that fact did not go unnoticed. The drug seemed to usher in a paradigm shift in the field of weight management.

Other g-lp receptor agonists, as they are called, soon followed.

Mugovey, Manjaro, Zepbound.

They helped millions of people do what they'd been unable to do before,

lose weight, seemingly without effort.

So demand for them surged, no surprise. And since their widespread use, so has our understanding of them.

The landscape has changed a lot since we first reported on these drugs on chasing life.

So today we're bringing back my friend and colleague, Meg Terrell, who has been

covering them since the start. She's going to update us on what is new, what's on the horizon.

Let me tell you, there's a lot to talk about. I'm CNN chief medical correspondent, Dr. Sanjay

Gupta, and this is chasing life.

Holland and Barrett's big payday event has landed.

So now's a good time to check in with your body.

Low on energy.

Tummy gurgling.

Struggling to focus.

Maybe your body's asking for a little more support.

This payday, give it what it needs,

with buy one, get one free,

...